Five-Year Financial Summary

In millions, except per share amounts 1997 1996 1995

1994

1993

Results of operations: (3)
Net sales $12,738.2 $10,944.8 $9,763.4 $8,762.0 $6,452.2
Operating profit 199.8 540.8 230.7 376.3 284.9
Comparable operating profit(1) 717.5 553.6 445.7 376.3 284.9
Earnings from continuing
     operations before
     extraordinary item
37.3 340.8 57.8 161.3 134.9
Comparable earnings from
     continuing operations before
     extraordinary item(2)
380.1 275.2 184.7 161.3 134.9
Net earnings (loss) 37.7 176.6 (572.8) 375.7 374.8
Net earnings (loss) available to
     common shareholders
24.0 162.1 (589.8) 358.7 358.0
Dividends declared 82.2 68.6 184.3 185.4 184.9

Per common share:
Earnings from continuing
     operations before
     extraordinary item:
Basic $0.14 $1.97 $0.25 $0.89 $0.79
Diluted 0.14 1.92 0.25 0.88 0.78
Comparable earnings from
     continuing operations:(2)
Basic 2.16 1.58 1.02 0.89 0.79
Diluted 2.12 1.55 1.02 0.88 0.78
Net earnings (loss):
Basic 0.14 0.98 (3.60) 2.21 2.39
Diluted 0.14 0.98 (3.59) 2.20 2.38
Dividends 0.44 0.44 1.52 1.52 1.52

Financial Position:
Total assets $5,636.9 $5,693.7 $6,335.6 $6,885.3 $5,318.8
Current liabilities 2,855.0 2,122.8 2,561.1 2,332.2 1,633.3
Total long-term obligations and
     redeemable preferred stock
274.1 1,254.6 1,092.6 991.4 565.9

Percentage of net sales:
Operating profit 1.6% 4.9% 2.4% 4.3% 4.4%
Comparable operating profit (1) 5.6 5.1 4.6 4.3 4.4
Earnings from continuing
     operations before
     extraordinary item
0.3 3.1 0.6 1.8 2.1
Comparable earnings from
     continuing operations before
     extraordinary item (2)
3.0 2.5 1.9 1.8 2.1
Net earnings (loss) 0.3 1.6 (5.9) 4.3 5.8

(1) Comparable operating profit excludes the pre-tax effect of the following non-recurring charges: (i) in 1997, $411.7 million ($273.7 million after-tax) related to the CVS/Revco Merger, $75.0 million ($49.9 million after-tax) related to the markdown of non-compatible Revco merchandise and $31.0 million ($19.1 million after-tax) related to the
restructuring of Big B, Inc., (ii) in 1996, $12.8 million ($6.5 million after-tax) related to the failed merger of Rite Aid Corporation and Revco and (iii) in 1995, $165.5 million ($97.7 million after-tax) related to the CVS Strategic Restructuring Program and the early adoption of SFAS No. 121 and $49.5 million ($29.1 million after-tax) related to the Company changing its policy from capitalizing internally developed software cost to expensing the costs as incurred, outsourcing certain technology functions and retaining certain employees until their respective job functions were transitioned.

(2) Comparable earnings from continuing operations before extraordinary item and comparable earnings per common share from continuing operations before extraordinary
item excludes the after-tax effect of the charges discussed in Note (1) above and the $121.4 million ($72.1 million after-tax) gain on sale of securities in 1996.

(3) Prior to the CVS/Revco Merger, Revco's fiscal year ended on the Saturday closest to May 31. In recording the business combination, Revco's consolidated financial statements have been restated to a December 31 year-end, to conform with CVS' fiscal year-end. As permitted by the rules and regulations of the Securities and Exchange Commission, Revco's fiscal years ended June 3, 1995 and May 28, 1994 have been combined with CVS' fiscal years ended December 31, 1994 and 1993.

 

home | visit our store | health care services | corporate info | investor info | employment | talk to us | site map

copyright ©1998 CVS/pharmacy, Inc.
For web site questions/comments, send e-mail to webmaster@cvs.com